Company intelligence / Profile preview

Traxxsson

St. Louis, Missouri, United States

Ownership: Private
Development stage: Other

Overview

Protein-based multi-cancer early detection (MCED) blood test achieved 100% sensitivity across breast, lung, colorectal, ovarian, and pancreatic cancers (including 100% Stage I detection), 97% specificity, and 98% tissue-of-origin accuracy in a study of 141 cancer patients and 119 controls.

Therapeutic areas: Oncology
Industry: Protein Biomarker Diagnostics

Beyond the preview

Go deeper on Traxxsson.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Traxxsson.

Explore the full profile